Addex leads chf 2 million investment in stalicla to advance precision medicine in neuropsychiatric disorders

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland – june 30, 2025 – addex therapeutics (six: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a chf 2 million investment in stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders.
ADXN Ratings Summary
ADXN Quant Ranking